检索结果-南通市图书馆

World Journal of Gastroenterology 2013年第37期19卷 6304-6309页

作者： Hong-Wei Wang Wen Yang Lin Wang Yun-Long Lu Jiang-Yang Lu Department of Pathology the First Affiliated HospitalChinese PLA General Hospital Department of Gynaecology and Obstetrics Chinese PLAGeneral Hospital

The combination of classical hodgkin’s lymphoma(cHL)and non-hodgkin lymphoma coexisting in the same patient is not common,especially in one extranodal *** we present a rare case of composite diffuse large B-cell lymphoma(DLBCL)and cHL occurring simultaneously in the stomach of a 53-year-old female who presented with upper abdominal discomfort and gas *** was performed and the disease was diagnosed pathologically as composite lymphoma of DLBCL and cHL using hematoxylin-eosin and immunohistochemical ***-Barr virus(EBV)infection was not detected by in situ hybridization for EBV-encoded RNA or immunohistochemistry for EBV latent membrane *** chain reaction analysis from the two distinct components of the tumor demonstrated clonal immunoglobulinκlight chain gene *** patient died approximately 11 mo after diagnosis in spite of receiving eight courses of the CHOP and two courses of the rituximab-CHOP(RCHOP) chemotherapy *** case report showed that the two distinct components,DLBCL and cHL,appeared to originate from the same clonal progenitor cell,and that EBV infection was not essential for transformation during the course of tumorigenesis.

关键词： Composite lymphoma Diffuse large B-cell lymphoma hodgkin’s lymphoma stomach

Current advances in hodgkin’s lymphoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chronic Diseases and Translational Medicine 2019年第1期5卷 15-24页

作者： Joseph Vadakara Benjamin Andrick Department of Hematology and Oncology Geisinger Medical Center Danville PA 17822 USA

hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy;however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of hodgkin’s lymphoma. This is a review of the current advances in the management of hodgkin’s lymphoma and a review of ongoing clinical trials in the field.

关键词： hodgkin’s lymphoma Brentuximab vedotin Nivolumab Pembrolizumab Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)

Involved Nodal Radiotherapy vs. Involved Field Radiotherapy after Chemotherapy in the Treatment of Early stage hodgkin’s Lymphoma

维普期刊数据库

同方期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2013年第1期4卷 271-279页

作者： Hamdy M. Zwam Emad E. Habib Mustafa E. AL-Daly Clinical Oncology Department Faculty of Medicine Cairo University Cairo Egypt

Aim of work: This study is a prospective randomized trial aiming to investigate whether radiotherapy volume can be reduced without loss of efficacy from involved field radiotherapy (IFRT) to involved node radiotherapy (INRT) after four cycles of ABVD chemotherapy in the treatment of early stage hodgkin’s lymphoma. Patients and Methods: Between september 2009 and January 2012, all patients with newly diagnosed early-stage favorable and unfavorable hodgkin’s lymphoma attending to the Clinical Oncology department of Cairo University, faculty of medicine were enrolled into this study after a written consent was obtained from those cases enrolled. Patients were assigned to receive (ABVD) for four cycles followed by randomization for radiotherapy into two arms one arm of 30 Gy INRT +/– 6 Gy to residual disease or another arm of 30 Gy IFRT +/– 6 Gy to residual disease. Results: 35 patients were enrolled in this study: 16 patients in the INRT arm and 19 patients in the IFRT arm. The median observation time was 25 months. The overall survival for all eligible patients was 97% and freedom from treatment failure was 85.7%. survival rates at the end of the study revealed no differences between INRT and IFRT arms. Also, in terms of complete remission post radiotherapy (14 versus 15), relapse (1 versus 4), and death (0 versus 1) respectively the outcome was similar in both arms. As regard acute and sub-acute toxicities no significant difference could be detected between both arms except that IFRT arm was associated with a higher incidence of radiation pneumonitis (4 versus 1 patient). Conclusion: Radiotherapy volume size reduction from IFRT to INRT after ABVD chemotherapy for four cycles produces similar results and less toxicity in patients with early-stage hodgkin’s lymphoma especially in patients with mediastinal disease.

关键词： hodgkin’s Lymphoma Nodal Radiotherapy Field Radiotherapy

Epidemiology of hodgkin’s lymphoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Health 2013年第5期5卷 17-22页

作者： Zahra Mozaheb Hematology-Oncology Department Imam-Reza Hospital Mashhad University of Medical Science Mashhad Iran

The epidemiology of hodgkin’s Lymphoma (HL) varies with age at clinical onset. In developing countries, the disorder appears predominantly during childhood and its incidence decreases with age, while in industrialized countries, the incidence rate increase with age. There has long been a view that the differences in descriptive epidemiology of hodgkin’s Lymphoma around the world, and also between children, young adults and older adults may reflect differences in etiology between them. hodgkin’s Lymphoma has long been suspected to have an infectious precursor, and indirect evidence has implicated Epstein-Barr virus (EBV), as a causal agent. The etiology of EBV-negative cases remains obscure. Epidemiological investigation of the etiology of hodgkin’s Lymphoma is making steady progress, and it leads to a better understanding and hence prevention. This review considers in detail the descriptive and the etiological epidemiology of hodgkin’s Lymphoma.

关键词： hodgkin’s Lymphoma-Epidemiology-Etiology

Low Dose Total Body Irradiation for Relapsed Low Grade Non-hodgkin’s Lymphoma: Experience of National Cancer Institute, Cairo

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2015年第1期6卷 25-33页

作者： Yasser Bayoumi Aida Radwan Radiation Oncology Department National Cancer Institute Cairo University Cairo Egypt Medical Physics Department National Cancer Institute Cairo University Cairo Egypt

Background and Purpose: The relapsed low grade non-hodgkin’s lymphoma (LG-NHL) is currently?incurable disease and the optimal treatment regimen has not determined yet. Low dose total body irradiation (LTBI) provides an alternative mechanism of action against cancer cells rather than direct cell kill. The mode of action of LTBI is immune-modulatory effect, induction of apoptosis and?hypersensitivity to low radiation doses. The aim of our study is to evaluate the effect of LTBI on relapsed?LG-NHL and reporting our experience at National Cancer Institute, Cairo (NCI, Cairo). Material and Methods: Fifty eight patients with relapsed LG-NHL and received LTBI studied retrospectively.?LTBI dose was 1.6 Gy/8 fractions divided on 2 courses;each course 4 fractions treated over 4 days with 2 weeks rest between the 2 courses. Results: The median age is 54 years;65% of the patients are men. Forty (69%) patients had performance status of 2 or more. Twenty seven patients were stage II/III and 31 patients (53%) had stage IV disease. Twenty six (45%) patients had bulky disease more than 10 cm and 22 (38%) patients had B symptoms at the time of relapse. The?extranodal disease was present in 17 patients (29%) and 78% of the patients received?>3 regimens of chemotherapy before referral to LTBI. Twenty three patients received IFRT (mean dose 32 ± 4 Gy) to initially bulky sites after LTBI. Fourteen patients (24%) achieved complete remission (CR) while 45%, 21% and 10% had partial remission (PR), stable disease (sD) and progressive disease (PD) respectively. The median PFs duration was 14 months and the median Os duration?was 39 months. stage VI,?>3 regimen of chemotherapy and bad response to LTBI (sD) affected?progression duration adversely (0.03, 0.05 and 0.01 respectively). The response to LTBI is the only factor affected the Os duration significantly. The 3-year PFs was 19% ± 9%, and 3-year Os was 45% ± 8%. stage IV was the only factor affected the 3-year PFs significantly with p value

关键词： Low Grade Non hodgkin’s Lymphoma [LG-NHL] Low Dose Total Body Irradiation [LTBI]

hodgkin's lymphoma coexisting with liver failure secondary to acute on chronic hepatitis B

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2013年第1期1卷 37-40页

作者： Renee Palta Amy McClune Karl Esrason Division of Gastrointestinal and Liver Disease Department of Transplant Hepatology Kaiser Permanente Los Angeles Medical Center Los Angeles CA 90027 United States Division of Hepatology University of California Los Angeles CA 94607 United States

Acute on chronic liver failure(ACLF) is rarely the initial manifestation of a malignant process or precipitated by the initiation of anti-viral treatment with a nucleoside or nucleotide agent. We report an unusual case of ACLF temporally associated with initiation of Entecavir for treatment of chronic hepatitis B. Early hodgkin's lymphoma(HL) was unmasked with initiation of the antiviral treatment which may have exacerbated ACLF. To the best of our knowledge, this has not been described in the literature. In reviewing our patients clinical course and liver autopsy, he developed a severe acute exacerbation of his chronic hepatitis B virus coinciding with the institution of antiviral therapy and the underlying HL perhaps modulating the overall degree of hepatic injury.

关键词： Entecavir Hepatic flare Fulminant hepatic failure Chronic hepatitis Acute liver failure hodgkin’s lymphoma

semen quality in Patients with hodgkin's disease versus non-hodgkin's lymPhoma before and after theraPy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Semen quality in Patients with Hodgkin's disease versus non-...

Rare case of sclerosing mesenteritis and low grade follicular lymphoma

第十六届全国泌尿外科学术会议

作者：王为服海南省人民医院

OBJECTIVE:hodgkins Disease(HD) and Non hodgkin’s LymPhoma(NHL) have a deleterious effect on semen quality and semen cryoPreservation,which is an imPortant comPonent of *** the documents

关键词： hodgkin’s disease/non-hodgkin’s lymphoma/sPerm cryoPreservation/sPermatogenesis/theraPy

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2016年第4期4卷 108-111页

作者： seema shah Gillian Mahy Enrico Roche the Townsville Hospital

An unusual case of long standing sclerosing mesenteritis;initially presented with recurrent abdominal pain and a mesenteric mass with surrounding fat oedema and stranding with a pseudocapsule and fat ring sign were clearly visualised on the initial computed tomography *** showed diffuse thickening at the root of the mesentery and histology from this specimen revealed fat necrosis and reactive lymphoid tissue consistent with sclerosing *** treatment with steroids and tamoxifen relieved the symptoms and the *** was maintained on *** years later he developed a recurrence of his symptoms and abdominal mass that responded to a course of *** years following this,he developed a follicular hodgkin’s lymphoma.

关键词： sclerosing mesenteritis Computerised tomography scan Magnetic resonance imaging scans Tamoxifen steroids hodgkin’s lymphoma

Rejection of Experimental hodgkins Lymphoma by T-Cells Engineered with a CD19 Chimeric Antigen Receptor

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2012年第5期3卷 553-561页

作者： Anna swanson Eleanor Cheadle David Gilham Dorothy Crawford simon Talbot Ingo Johannessen 5Laboratory Medicine (Virology) Royal Infirmary of Edinburgh Edinburgh UK The University of Edinburgh Centre for Infectious Diseases Edinburgh UK The University of Edinburgh Division of Pathway Medicine Chancellor’s Building Edinburgh UK The University of Manchester Clinical and Experimental Immunology Group Manchester UK

T cells engineered to express chimeric antigen receptors (CARs) combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) signaling domain for triggering cell activation are being used for immunotherapeutic targeting of tumor cells in a non-HLA restricted manner. In this study we transduced T cells with a CD19-CAR construct containing a truncated CD34 gene (tCD34) marker and used these to target the B cell antigen CD19 on the surface of a hodgkin’s lymphoma (HL) cell line (L591) both in vitro and in vivo. Levels of tCD34 expression in transduced peripheral blood mononuclear cells (PBMCs) ranged from 6% - 20% and this was increased to 82% after selection for transduced tCD34+ cells. In vitro cytotoxicity testing on a CD19+ HL cell line (L591) showed specific cell lysis initiated by the CD19-CAR transduced PBMCs. Importantly, CD19-CAR T cells prevented the growth of L591 HL tumor cells when co-injected subcutaneously (sc) in 6/6 severe combined immunodeficient (sCID) mice. There was no evidence of anti-tumor activity when CD19-CAR T cells were infused intravenously (iv) at the same time as L591 HL tumor cells were injected sc. However, 3/6 sCID mice showed tumor rejection within 83 days after iv infusion of CD19-CAR T cells 3 - 9 days after establishment of L591 HL tumors, while all control animals succumbed to tumors within 60 days. Interestingly, immuno-histochemical analysis of L591 HL tumors demonstrated that CD19-CAR T cells were detected not earlier than 11 days after infusion within the tumor mass. These results suggest that CD19 is a potentially attractive target for the immunotherapy of HL.

关键词： hodgkin’s Lymphoma CD19 Chimeric Antigen Receptor Immunotherapy

Post Liver Transplantation Lympho Proliferative Disorder, Classical hodgkins Lymphoma Type—A Case Report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Clinical Medicine 2014年第18期5卷 1142-1145页

作者： Indu R. Nair Annie Jojo sudhindran surendran Dinesh Balakrishnan Department of Pathology Amrita Institute of Medical Sciences Amrita Viswavidyapeetam Kochi India Department of surgical Gastroenterology Amrita Institute of Medical Sciences Amrita Viswavidyapeetam Kochi India

Post transplantation lymphoproliferative disorder is a lymphoid/plasmacytic proliferation that develops as a consequence of immunosuppression in a recipient of a solid organ/bone marrow/stem cell allograft. The incidence reported in literature in post liver transplant patients is 1% - 2%. This case was of a 16-year-old boy who underwent liver transplantation for fulminant hepatic failure and subsequently developed PTLD. Morphologically and immunohistochemically, it was hodgkin’s lymphoma like PTLD, which was the least common type reported in literature.

关键词： Liver Transplant Post Transplant Lymphoproliferative Disorder Classical hodgkin’s Lymphoma Like